Bokf Na Sells 18,412 Shares of Pfizer Inc. (NYSE:PFE)

BOKF NA cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 124,661 shares of the biopharmaceutical company's stock after selling 18,412 shares during the period. BOKF NA's holdings in Pfizer were worth $3,331,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC increased its stake in shares of Pfizer by 7.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 695,003 shares of the biopharmaceutical company's stock worth $18,438,000 after purchasing an additional 47,293 shares during the last quarter. Bridger Management LLC lifted its position in shares of Pfizer by 33.0% in the fourth quarter. Bridger Management LLC now owns 466,059 shares of the biopharmaceutical company's stock worth $12,365,000 after buying an additional 115,559 shares during the last quarter. Blue Capital Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $595,000. Brevan Howard Capital Management LP raised its stake in shares of Pfizer by 167.0% in the 4th quarter. Brevan Howard Capital Management LP now owns 222,421 shares of the biopharmaceutical company's stock valued at $5,901,000 after acquiring an additional 139,109 shares in the last quarter. Finally, Cahill Financial Advisors Inc. lifted its holdings in Pfizer by 60.4% in the 4th quarter. Cahill Financial Advisors Inc. now owns 15,284 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 5,756 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

Pfizer stock traded down $0.69 during mid-day trading on Friday, hitting $22.28. 38,991,216 shares of the company were exchanged, compared to its average volume of 40,465,709. The company has a market capitalization of $126.36 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The business has a fifty day moving average of $24.02 and a 200 day moving average of $25.56. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.72%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.